Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 232 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malabsorption Disorders Clear all
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Bovine Colostrum to Prevent Absorption of Gluten

NCT05555446
View directory record Official record
Conditions
Celiac Disease, Gluten Sensitivity, Non-celiac Gluten Sensitivity
Interventions
Bovine colostrum, Placebo
Dietary Supplement
Lead sponsor
Milky Way Life Sciences LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System

NCT04573959
View directory record Official record
Conditions
Intestinal Disease, Inflammatory Bowel Diseases, Crohn Disease, Ulcer, Celiac Disease
Interventions
SV-3 Capsule Endoscopy
Device
Lead sponsor
Capso Vision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Saratoga, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 5, 2026, 3:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

NCT05660278
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 5, 2026, 3:13 PM EDT
Terminated Phase 4 Interventional Results available

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

NCT00742157
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Growth Hormone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 78 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 5, 2026, 3:13 PM EDT
Completed No phase listed Observational

Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing

NCT01324895
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

NCT00513682
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT20
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Not applicable Interventional

Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?

NCT01891279
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
elemental formula Elecare®, partially hydrolyzed formula
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 1 Year
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 5, 2026, 3:13 PM EDT
Terminated Phase 4 Interventional Results available

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369
View directory record Official record
Conditions
Celiac Disease
Interventions
pancrelipase
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 1 Interventional

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

NCT00263237
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 1 Interventional

Safety Study of Larazotide Acetate to Treat Celiac Disease.

NCT00386165
View directory record Official record
Conditions
Celiac Disease
Interventions
larazotide acetate
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 5, 2026, 3:13 PM EDT
Completed No phase listed Observational

Virtual Celiac Symptoms Study in Adults and Teenagers

NCT05309330
View directory record Official record
Conditions
Celiac Disease
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

NCT03563846
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 5, 2026, 3:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

NCT00172185
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide 0.05 mg/kg/d, teduglutide 0.10 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

NCT02673749
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebo
Drug · Other
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 5, 2026, 3:13 PM EDT
Terminated Not applicable Interventional

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

NCT03451253
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Short Bowel Syndrome, Ileostomy - Stoma
Interventions
amino acid mixture beverage, glucose-based sports drink
Other
Lead sponsor
Entrinsic Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Nashua, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Not applicable Interventional Results available

Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp

NCT01930539
View directory record Official record
Conditions
Vitamin D Deficiency, Short Bowel Syndrome
Interventions
Ultraviolet B lamp
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 5, 2026, 3:13 PM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 5, 2026, 3:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Genepro Generation 3 Protein Bioavailability Compared to Whey Protein

NCT04615858
View directory record Official record
Conditions
Absorption; Disorder, Protein, Protein Malabsorption, Protein Intolerance
Interventions
Genepro Generation 3 Protein, Whey Protein
Dietary Supplement
Lead sponsor
Musclegen Research, Inc.
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cary, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 5, 2026, 3:13 PM EDT
Enrolling by invitation Phase 4 Interventional

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

NCT07583342
View directory record Official record
Conditions
Acute Pancreatitis (AP), Enhancing Enteral Nutrition Tolerance
Interventions
RELiZORB digestive enzyme (immobilized lipase) cartridge
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Manhattan, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia

NCT00399191
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
stable isotope of iron, dysprosium
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
20 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Sep 5, 2026, 3:13 PM EDT
Completed Not applicable Interventional

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

NCT01932476
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Gluten Challenge, Sham Challenge
Dietary Supplement
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 5, 2026, 3:13 PM EDT
Not listed Not applicable Interventional

Pectin Use in Pediatric Intestinal Rehabilitation

NCT04224168
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Green Beans, Liquid Pectin
Dietary Supplement
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
6 Months to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 5, 2026, 3:13 PM EDT